SCHEMBL25009152

SCHEMBL25009152

CC(=O)c1c(N)cc(Cl)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
KMT2A Q03164 4/20 0.37
NPC1 O15118 2/20 0.37
PKM P14618 2/20 0.37
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ABL1 P00519 1/20 0.36
ALDH1A1 P00352 3/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HDAC1 Q13547 1/20 0.35
ADORA2A P29274 1/20 0.35
MEN1 O00255 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 2/20 0.33
THRB P10828 1/20 0.33
SPR P35270 1/20 0.33
FADS1 O60427 1/20 0.33
APP P05067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30699260 1.00 CYP3A4 (0.40) CYP3A4KMT2ANPC1PKMRAB9A
SCHEMBL3028979 0.86 NPC1 (0.41) CYP3A4KMT2ANPC1PKMRAB9A
SCHEMBL1398127 0.82 CYP3A4 (0.41) CYP3A4KMT2AABL1ALDH1A1POLB
SCHEMBL1398086 0.82 CYP3A4 (0.50) CYP3A4KMT2AABL1ALDH1A1POLB
SCHEMBL18534545 0.81 CYP3A4 (0.32) CYP3A4ALDH1A1SMN1; SMN2HPGDALOX15
SCHEMBL23601385 0.80 ABL1 (0.51) CYP3A4KMT2ANPC1RAB9AABL1
SCHEMBL29921597 0.80 CES2 (0.38) CYP3A4KMT2ANPC1RAB9AALDH1A1
SCHEMBL21178071 0.80 CES2 (0.38) CYP3A4KMT2ANPC1RAB9AALDH1A1
SCHEMBL3019010 0.78 KMT2A (0.48) CYP3A4KMT2ANPC1PKMRAB9A
SCHEMBL32665702 0.78 CYP3A4 (0.50) CYP3A4KMT2ANPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331678-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2023-10-19 US disclosed
WO-2023172845-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. (US) 2023-09-14 WO disclosed
WO-2023014861-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. (US) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331678-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD CYP3A4 616/4885KMT2A 4163/4885NPC1 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.